This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06200467 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Boehringer Ingelheim |
| Enrollment | 110 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Overweight; Obesity |
| Interventions | BI 456906; Placebo to BI 456906; Moxifloxacin; Placebo to moxifloxacin |
| Start | Mar 13, 2024 |
| Primary completion | Oct 22, 2025 |
| Study completion | Oct 22, 2025 |
| Results posted | Not yet |
| Registry last updated | Mar 13, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study is open to adults between 18 and 55 years of age with overweight or obesity. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) has an effect on cardiac safety. When a new medicine is developed, it is important to check whether it affects the heart. Moxifloxacin is a medicine that is known to change the heart rhythm. In this study, moxifloxacin is used as a so-called positive control.
Participants are put into 3 groups by chance. There is a different treatment schedule for each of the groups. All participants start with one placebo injection under their skin. The next day, depending on the group, participants take either moxifloxacin or placebo as a tablet. Then, for about 30 weeks, participants receive survodutide or placebo as an injection under their skin once a week. After this, they take again a single dose of moxifloxacin or placebo.
Participants are in the study for up to 9 months. During this time, they visit the study site regularly. For 2 of the visits, participants stay at the study site for 2 nights. During these visits, the doctors collect information about participants' health. To assess the study endpoints, the study staff regularly performs ECG tests. The doctors also regularly check participants' health and take note of any unwanted effects.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Time-matched QTcI change from baseline (u0394QTcI) collected at the same time points as the BI 456906 plasma concentrations up to a maximum of 30 weeks after first drug administration of BI 456906 / BI 456906-placebo | up to 30 weeks. |
2 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
